title: Is irritable bowel syndrome an infectious disease?
abstract: Irritable bowel syndrome (IBS) is the most common of all gastroenterological diseases. While many mechanisms have been postulated to explain its etiology, no single mechanism entirely explains the heterogeneity of symptoms seen with the various phenotypes of the disease. Recent data from both basic and clinical sciences suggest that underlying infectious disease may provide a unifying hypothesis that better explains the overall symptomatology. The presence of small intestinal bowel overgrowth (SIBO) has been documented in patients with IBS and reductions in SIBO as determined by breath testing correlate with IBS symptom improvement in clinical trials. The incidence of new onset IBS symptoms following acute infectious gastroenteritis also suggests an infectious cause. Alterations in microbiota-host interactions may compromise epithelial barrier integrity, immune function, and the development and function of both central and enteric nervous systems explaining alterations in the brain-gut axis. Clinical evidence from treatment trials with both probiotics and antibiotics also support this etiology. Probiotics appear to restore the imbalance in the microflora and improve IBS-specific quality of life. Antibiotic trials with both neomycin and rifaximin show improvement in global IBS symptoms that correlates with breath test normalization in diarrhea-predominant patients. The treatment response to two weeks of rifaximin is sustained for up to ten weeks and comparable results are seen in symptom reduction with retreatment in patients who develop recurrent symptoms.
authors.affiliation: John Richard Thompson, Department of Pharmacy Practice, Lipscomb University College of Pharmacy, One University Park Drive, Nashville, TN 37204, United States.
authors.forename: John Richard
authors.initials: JR
authors.lastname: Thompson
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects / Q000254:growth & development*; D064806:Dysbiosis; D000069196:Gastrointestinal Microbiome / Q000187:drug effects; D054884:Host-Pathogen Interactions; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000382:microbiology* / Q000503:physiopathology; D043183:Irritable Bowel Syndrome / Q000175:diagnosis / Q000382:microbiology* / Q000503:physiopathology / Q000628:therapy; D019936:Probiotics / Q000627:therapeutic use; D012074:Remission Induction; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents
keywords: Antibiotics; Etiology; Infectious disease; Irritable bowel syndrome; Pathopohysiology; Probiotics
references.citation: Am J Gastroenterol. 2007 Apr;102(4):837-41
references.pmid: 17397408
references.citation: Aliment Pharmacol Ther. 2007 Aug 1;26(3):475-86
references.pmid: 17635382
references.citation: Curr Treat Options Gastroenterol. 2007 Aug;10(4):328-37
references.pmid: 17761126
references.citation: Lancet. 1998 Oct 10;352(9135):1187-9
references.pmid: 9777836
references.citation: Gut. 2013 Jan;62(1):159-76
references.pmid: 22730468
references.citation: Eur J Gastroenterol Hepatol. 2002 Jul;14(7):753-6
references.pmid: 12169984
references.citation: Gut. 2007 Nov;56(11):1522-8
references.pmid: 17339238
references.citation: JAMA. 2004 Aug 18;292(7):852-8
references.pmid: 15316000
references.citation: World J Gastroenterol. 2014 Jul 14;20(26):8709-16
references.pmid: 25024629
references.citation: Aliment Pharmacol Ther. 2008 Jan 1;27(1):48-57
references.pmid: 17919270
references.citation: Cell Host Microbe. 2007 Sep 13;2(3):204
references.pmid: 18030708
references.citation: World J Gastroenterol. 2014 Mar 14;20(10):2482-91
references.pmid: 24627585
references.citation: JAMA. 2015 Mar 3;313(9):949-58
references.pmid: 25734736
references.citation: J Neurogastroenterol Motil. 2010 Jan;16(1):40-6
references.pmid: 20535325
references.citation: World J Gastroenterol. 2014 Jul 21;20(27):8859-66
references.pmid: 25083059
references.citation: Aliment Pharmacol Ther. 2007 Aug 15;26(4):535-44
references.pmid: 17661757
references.citation: World J Gastroenterol. 2014 Nov 7;20(41):15163-76
references.pmid: 25386066
references.citation: Am J Gastroenterol. 2003 Feb;98(2):412-9
references.pmid: 12591062
references.citation: N Engl J Med. 2011 Jan 6;364(1):22-32
references.pmid: 21208106
references.citation: World J Gastroenterol. 2014 Jul 21;20(27):8846-58
references.pmid: 25083058